Regeneron Genetic Medicines is dedicated to advancing the understanding and application of genetic therapies to treat serious diseases and conditions. We are seeking an experienced and talented Associate Scientist to join our Regeneron Genetic Medicines (RGM) Chemistry team.
In this role, you will be able to contribute to the advancement of RNA therapeutic technologies and assist in developing and applying robust on and off bead synthetic organic methodologies. Specifically, you will support the synthesis of RNA-related platform technologies for a variety of programs.
As an Associate Scientist, a typical day might include the following:
Synthesis of variable lengths and formats of oligonucleotides on automated synthesizers, incorporating novel or standard amidites and ligands on and off bead.
Applying ideas from different addresses to solve complex chemical problems.
Performing purification and characterization using conventional and industry-leading instrumentation.
Maintaining synthesizers and related supplies.
Are passionate about scientific research and wish to enhance our drug discovery process.
Have a passion for innovation and desire to lead new scientific directions.
Are a teammate with a collaborative spirit.
Are confident with multitasking and balancing multiple projects simultaneously.
Excel at communicating with diverse audiences, including scientists in multiple fields.
To be considered for this position, you must have a Masters or Bachelors in synthetic organic chemistry with 2-5+ years of experience in a discovery or development setting. A strong background in modern organic synthesis, chromatography, and analytical techniques including ion-pair reverse phase chromatography, ion exchange chromatography, HPLC, MS, LC/MS and NMR is preferred.
Salary Range (annually)
For 30 years, our mission has been to use the power of science to bring new medicines to patients.... over and over again. Every day, we apply our homegrown technologies and relentless spirit to help people with serious diseases.
28 jobsSubscribe to Rise newsletter